Fundraising Fox

Serina Therapeutics

NYSE: SER

Huntsville, US · Alabama corporation · 1 known investors

Serina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.

BiotechDeep TechHealthtech

Founders & leadership

JM
J Milton HarrisFounder
RW
Randall W MoreadithExecutive
TV
Tacey ViegasExecutive
MD
Michael D BentleyNamed on SEC filing

Board

MA
Miguel A LoyaBoard director
JR
James R Hudson, Jr.Board director
BF
Barbara FiskBoard director

Investors · 1

New Capital PartnersBirmingham · $5M – $100M

Reported raises · per SEC filings

Form D private placements

$31.4M disclosed across 6 rounds · 2014–2023

▶$10MraisedMar 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara M FiskDirector
  • James R Hudson, Jr.Director
  • Randall W MoreadithExecutive Officer, Director
  • Steve LedgerDirector
  • Greg H Bailey, M.D.Director
  • J Milton HarrisExecutive Officer, Director
  • Tacey ViegasExecutive Officer
  • Michael D BentleyExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
First sale
Mar 2023
Incorporated
Corporation, Alabama
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.6MraisedNov 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Miguel A LoyaDirector
  • Randall W MoreadithExecutive Officer, Director
  • James R Hudson, Jr.Director
  • Michael D BentleyExecutive Officer, Director
  • J Milton HarrisExecutive Officer, Director
  • Barbara FiskDirector
  • Tacey ViegasExecutive Officer
Offering amount
$3.6M
Amount sold
$3.6M
First sale
Nov 2022
Incorporated
Corporation, Alabama
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1MraisedJul 2022 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Barbara FiskDirector
  • Miguel A LoyaDirector
  • James R Hudson, Jr.Director
  • Randall W MoreadithExecutive Officer, Director
  • Tacey ViegasExecutive Officer
  • Michael D BentleyExecutive Officer, Director
  • J Milton HarrisExecutive Officer, Director
Offering amount
$5M
Amount sold
$1M
First sale
Jun 2022
Incorporated
Corporation, Alabama
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.7MraisedJun 2021 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael D BentleyExecutive Officer, Director
  • James R Hudson, Jr.Director
  • Randall W MoreadithExecutive Officer, Director
  • J Milton HarrisExecutive Officer, Director
  • Barbara FiskDirector
  • Miguel A LoyaDirector
  • Tacey ViegasExecutive Officer
Offering amount
$76.2M
Amount sold
$3.7M
First sale
Jul 2019
Incorporated
Corporation, Alabama
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.2MraisedApr 2018 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James R Hudson, Jr.Director
  • Michael D BentleyExecutive Officer, Director
  • Barbara FiskDirector
  • J Milton HarrisExecutive Officer, Director
  • Miguel A LoyaDirector
  • Tacey ViegasExecutive Officer
  • Randall W MoreadithExecutive Officer, Director
  • Brendan RaeExecutive Officer
Offering amount
$32.5M
Amount sold
$8.2M
First sale
Jan 2017
Incorporated
Corporation, Alabama
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.9MraisedMar 2015 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Tacey ViegasExecutive Officer
  • J Milton HarrisExecutive Officer, Director
  • James R Hudson, Jr.Director
  • Randall W MoreadithExecutive Officer, Director
  • Barbara FiskDirector
  • Michael D BentleyExecutive Officer, Director
Offering amount
$6.3M
Amount sold
$4.9M
First sale
Apr 2014
Incorporated
Corporation, Alabama
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap
Sionnatx16 shared keywordsSionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs. It is advancing a portfolio of NBD1 stabilizers and complementary CFTR modulators intended to be used in combination to normalize CFTR function in CF patients.
Serna Bio13 shared keywordsSerna builds a platform to unlock the transcriptome as a drug target for drug discovery. The company integrates technology and biology to change drug discovery processes.
Day One Biopharmaceuticals11 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Switch Therapeutics11 shared keywordsSwitch Therapeutics develops RNA interference (RNAi) therapeutic applications targeting central nervous system diseases, leveraging research from Caltech, Harvard Medical School, and City of Hope.
Neurona Therapeutics9 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter> <parameter name="founders">[]
Syrna Therapeutics8 shared keywordsSyrna Therapeutics is a biotech company developing small-molecule covalent translation inhibitors that bind and modify structured domains in the mRNA of disease-causing proteins to block their expression. It uses a 3D structure-guided drug discovery platform, with lead programs in immunology and neurodegeneration and a broader pipeline spanning metabolic disease and oncology.

Companies competing with Serina Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Serina Therapeutics do?
Serina Therapeutics is a clinical-stage biotechnology company developing its POZ Platform, a polymer technology ("POZylation") that modifies proven small molecule drugs to enable controlled, sustained release with fewer side effects. Its lead candidate, SER-252 (POZ-apomorphine), targets advanced Parkinson's disease, and the platform is also applied to CNS indications and RNA medicines.
Who founded Serina Therapeutics?
Serina Therapeutics was founded by J Milton Harris.
Who are Serina Therapeutics's investors?
Serina Therapeutics's investors include New Capital Partners.
How much funding has Serina Therapeutics raised?
Serina Therapeutics has disclosed $31.4M raised across 6 rounds.
Where is Serina Therapeutics headquartered?
Serina Therapeutics is headquartered in Huntsville, US.